{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.1","upperLimit":"30.5","value":"21.5"},{"groupId":"OG001","lowerLimit":"15.9","upperLimit":"41.7","value":"27.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"Complete remission was defined as the proportion of participants who achieved a CR or Complete Remission with Incomplete Marrow Recovery(CRi ) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a CR or CRi were considered to be non-responders in the calculation of CR rate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG000","title":"Main Cohort"},{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG001","title":"Safety Expansion Cohort"}],"paramType":"NUMBER","populationDescription":"All treated participants in the Main Cohort and the Safety Expansion Cohort","reportingStatus":"POSTED","timeFrame":"Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up","title":"Complete Remission (CR) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}